Support your patients as they commit to long-term treatment with Aldurazyme.
A long-term commitment
Patients and caregivers need to understand that staying on track with Aldurazyme infusions is an important part of the overall mucopolysaccharidosis type I (MPS I) management.1-3
- Patients may need to receive ongoing infusions of Aldurazyme, even if their symptoms improve3,4
- If long-term treatment is stopped, GAG levels may rise again, creating a recurrence of MPS I signs and symptoms3,4

Actor portrayal.
When discussing MPS I with your patients, cover the following points1,5:
- MPS I patients need long-term care. It is important that we understand and address patients' concerns for better long-term care
- You could explain in patient-friendly terms that people with MPS I are deficient in the enzyme IDUA, which is responsible for breaking down the accumulation of GAG. When Aldurazyme is administered, it supplies the body with a source of the deficient enzyme and helps break down that accumulation of GAG. If the therapy is stopped, GAG can once again build up, which may lead to a recurrence of certain signs and symptoms
- It is important to continue to monitor your patients' disease progression. Due to the progressive nature of MPS I, patients may need to receive ongoing infusions of Aldurazyme, even if their symptoms have improved
- Patients and their families may expect quick results with Aldurazyme therapy. Consider explaining how results vary based on each patient’s own condition and response to the treatment. To maintain treatment benefit, Aldurazyme should be administered weekly as indicated
GAG=glycosaminoglycan; IDUA= α-L-iduronidase; MPS I=mucopolysaccharidosis type I.
Indication
References: 1. Aldurazyme (laronidase). Prescribing Information. Sanofi. 2. Martins AM et al. J Pediatr. 2009;155(4)(suppl 2):S32-S46. 3. Anbu AT et al. J Inherit Metab Dis. 2006;29(1):230-231. 4. Laraway S et al. Outcomes of long-term treatment with laronidase in patients with mucopolysaccharidosis type I. J Pediatr. 2016;178:219-226.e1. 5. Neufeld EF, Muenzer J. The Mucopolysaccharidoses. In: Valle DL, Antonarakis S, Ballabio A, Beaudet AL, Mitchell GA. eds. The Online Metabolic and Molecular Bases of Inherited Disease. McGraw Hill; 2019. Accessed July 20, 2022. https://ommbid.mhmedical.com/content.aspx?bookid=2709§ionid=225544161